The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Efficacy and safety of tanezumab in the treatment of chronic low back pain
Abstract
Increased nerve growth factor levels are associated with chronic pain conditions, including chronic low back pain (LBP). This study examined safety and analgesic efficacy of tanezumab, a humanized anti-nerve growth factor antibody, in adults with chronic LBP. Patients received intravenous tanezumab 200 μg/kg plus oral placebo (n=88), intravenous placebo plus oral naproxen 500 mg twice a day (n=88), or intravenous placebo plus oral placebo (n=41). Primary outcome was average LBP intensity (aLBPI) at Week 6. Secondary outcomes were proportion of patients with ≥30% or ≥50% reduction in aLBPI, Roland-Morris Disability Questionnaire and Brief Pain Inventory-short form scores, Patients' Global Assessment of LBP, Patients' Global Evaluation of study medication, and rescue medication use. Mean aLBPI change from baseline to Week 6 was greater with tanezumab vs naproxen (P=0.004) and placebo (P<0.001). Greater proportions of patients reported ≥30% and ≥50% reduction in aLBPI with tanezumab vs naproxen (P≤0.013) and placebo (P<0.001), and greater improvements in Roland-Morris Disability Questionnaire (P<0.001) and other secondary outcomes except rescue medication use. Tanezumab was associated with adverse events (AEs) of abnormal peripheral sensation that were generally mild and resolved before study completion; however, there were no serious AEs. Nine patients (4 of whom were tanezumab-treated) discontinued due to AEs. In conclusion, tanezumab resulted in analgesic efficacy that was clinically and statistically superior to placebo and naproxen in patients with chronic LBP. Tanezumab clinical development is on regulatory hold due to AEs in osteoarthritis patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Study of the Natural History of Back Pain: Part I
ROLAND, M., & MORRIS, R. (1983) · Spine · doi:10.1097/00007632-198303000-00004 · Cited by 3,395 · cited 1×
“measure of function and performance of daily activities in patients with LBP, is a series of 24 yes/no questions scored as the sum of ‘‘yes’’ responses (lower score indicates better function) [21].”
BackgroundChou, R., Qaseem, A., Snow, V., Casey, D., Cross, J. T., Shekelle, P., Owens, D. K., & for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians and the American College of Physicians/American Pain Society Low Back Pain Guidelines Panel* (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-7-200710020-00006 · Cited by 2,718
Chapter 4 European guidelines for the management of chronic nonspecific low back pain
Airaksinen, O., Brox, J. I., Cedraschi, C., Hildebrandt, J., Klaber-Moffett, J., Kovacs, F., Mannion, A. F., Reis, S., Staal, J. B., Ursin, H., et al. (2006) · European Spine Journal · doi:10.1007/s00586-006-1072-1 · Cited by 2,594
Deyo, R. A., & Weinstein, J. N. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440508 · Cited by 1,675
Benedict, R. H. B., Schretlen, D., Groninger, L., & Brandt, J. (1998) · The Clinical Neuropsychologist · doi:10.1076/clin.12.1.43.1726 · Cited by 1,597
Chou, R., Loeser, J. D., Owens, D. K., Rosenquist, R. W., Atlas, S. J., Baisden, J., Carragee, E. J., Grabois, M., Murphy, D. R., Resnick, D. K., et al. (2009) · Spine · doi:10.1097/brs.0b013e3181a1390d · Cited by 581 · cited 2×
“Pharmacotherapy is an important component of the overall treatment approach; however, many medications are associated with undesirable consequences, including medication-related side effects and complications [5,7,17,20].”
BackgroundChou, R., Atlas, S. J., Stanos, S. P., & Rosenquist, R. W. (2009) · Spine · doi:10.1097/brs.0b013e3181a103b1 · Cited by 392 · cited 1×
“Pharmacotherapy is an important component of the overall treatment approach; however, many medications are associated with undesirable consequences, including medication-related side effects and complications [5,7,17,20].”
Background
Cited by
Qaseem, A., Wilt, T. J., McLean, R. M., Forciea, M. A., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m16-2367 · Cited by 3,234
Chou, R., Deyo, R., Friedly, J., Skelly, A., Weimer, M., Fu, R., Dana, T., Kraegel, P., Griffin, J., & Grusing, S. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2458 · Cited by 864
Lyu, F.-J., Cui, H., Pan, H., MC Cheung, K., Cao, X., Iatridis, J. C., & Zheng, Z. (2021) · Bone Research · doi:10.1038/s41413-020-00125-x · Cited by 474
Clinical targeting of the TNF and TNFR superfamilies
Croft, M., Benedict, C. A., & Ware, C. F. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3930 · Cited by 456
An Overview of Animal Models of Pain: Disease Models and Outcome Measures
Gregory, N. S., Harris, A. L., Robinson, C. R., Dougherty, P. M., Fuchs, P. N., & Sluka, K. A. (2013) · The Journal of Pain · doi:10.1016/j.jpain.2013.06.008 · Cited by 435
Metadata
- Authors
- Katz, N., Borenstein, D. G., Birbara, C., Bramson, C., Nemeth, M. A., Smith, M. D., & Brown, M. T.
- Venue
- Pain
- Published
- 2011-10
- Volume
- 152
- Issue
- 10
- Pages
- 2248-2258
- ISSN
- 0304-3959 (ISSN-L)
- OpenAlex
- W2091349116
- Cited by
- 243
- References
- 7
- FWCI
- 16.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.